BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 15099659)

  • 1. Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence.
    González S; Fernández-Ruiz J; Di Marzo V; Hernández M; Arévalo C; Nicanor C; Cascio MG; Ambrosio E; Ramos JA
    Drug Alcohol Depend; 2004 May; 74(2):159-70. PubMed ID: 15099659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time course of the effects of different cannabimimetics on prolactin and gonadotrophin secretion: evidence for the presence of CB1 receptors in hypothalamic structures and their involvement in the effects of cannabimimetics.
    Fernández-Ruiz JJ; Muñoz RM; Romero J; Villanua MA; Makriyannis A; Ramos JA
    Biochem Pharmacol; 1997 Jun; 53(12):1919-27. PubMed ID: 9256167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats.
    Di Marzo V; Berrendero F; Bisogno T; González S; Cavaliere P; Romero J; Cebeira M; Ramos JA; Fernández-Ruiz JJ
    J Neurochem; 2000 Apr; 74(4):1627-35. PubMed ID: 10737621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist.
    Tsou K; Patrick SL; Walker JM
    Eur J Pharmacol; 1995 Jul; 280(3):R13-5. PubMed ID: 8566091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs.
    Stewart JL; McMahon LR
    J Pharmacol Exp Ther; 2010 Jul; 334(1):347-56. PubMed ID: 20375197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration.
    Falenski KW; Thorpe AJ; Schlosburg JE; Cravatt BF; Abdullah RA; Smith TH; Selley DE; Lichtman AH; Sim-Selley LJ
    Neuropsychopharmacology; 2010 Jul; 35(8):1775-87. PubMed ID: 20357755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sex steroid influence on cannabinoid CB(1) receptor mRNA and endocannabinoid levels in the anterior pituitary gland.
    González S; Bisogno T; Wenger T; Manzanares J; Milone A; Berrendero F; Di Marzo V; Ramos JA; Fernández-Ruiz JJ
    Biochem Biophys Res Commun; 2000 Apr; 270(1):260-6. PubMed ID: 10733937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
    Lichtman AH; Sheikh SM; Loh HH; Martin BR
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1007-14. PubMed ID: 11504797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of endocannabinoid receptor agonist anandamide and antagonist rimonabant on opioid analgesia and tolerance in rats.
    Altun A; Ozdemir E; Yildirim K; Gursoy S; Durmus N; Bagcivan I
    Gen Physiol Biophys; 2015 Oct; 34(4):433-40. PubMed ID: 26374993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice.
    Yamaguchi T; Hagiwara Y; Tanaka H; Sugiura T; Waku K; Shoyama Y; Watanabe S; Yamamoto T
    Brain Res; 2001 Aug; 909(1-2):121-6. PubMed ID: 11478928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apparent affinity estimates of rimonabant in combination with anandamide and chemical analogs of anandamide in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
    McMahon LR
    Psychopharmacology (Berl); 2009 Apr; 203(2):219-28. PubMed ID: 18592221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
    Cabranes A; Venderova K; de Lago E; Fezza F; Sánchez A; Mestre L; Valenti M; García-Merino A; Ramos JA; Di Marzo V; Fernández-Ruiz J
    Neurobiol Dis; 2005 Nov; 20(2):207-17. PubMed ID: 16242629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corticotropin-releasing hormone (CRH) mRNA expression in rat central amygdala in cannabinoid tolerance and withdrawal: evidence for an allostatic shift?
    Caberlotto L; Rimondini R; Hansson A; Eriksson S; Heilig M
    Neuropsychopharmacology; 2004 Jan; 29(1):15-22. PubMed ID: 12968131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTP gamma S binding and cannabinoid receptor mRNA levels in the basal ganglia and the cerebellum of adult male rats chronically exposed to delta 9-tetrahydrocannabinol.
    Romero J; Berrendero F; García-Gil L; Ramos JA; Fernández-Ruiz JJ
    J Mol Neurosci; 1998 Oct; 11(2):109-19. PubMed ID: 10096037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of AM1346, a high-affinity CB1 receptor selective anandamide analog, on open-field behavior in rats.
    Järbe TU; DiPatrizio NV; Li C; Makriyannis A
    Behav Pharmacol; 2007 Nov; 18(7):673-80. PubMed ID: 17912052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoid influences on palatability: microstructural analysis of sucrose drinking after delta(9)-tetrahydrocannabinol, anandamide, 2-arachidonoyl glycerol and SR141716.
    Higgs S; Williams CM; Kirkham TC
    Psychopharmacology (Berl); 2003 Feb; 165(4):370-7. PubMed ID: 12447606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol.
    Romero J; García L; Fernández-Ruiz JJ; Cebeira M; Ramos JA
    Pharmacol Biochem Behav; 1995 Aug; 51(4):731-7. PubMed ID: 7675852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoid receptor binding and mRNA levels in several brain regions of adult male and female rats perinatally exposed to delta9-tetrahydrocannabinol.
    García-Gil L; Romero J; Ramos JA; Fernández-Ruiz JJ
    Drug Alcohol Depend; 1999 Jun; 55(1-2):127-36. PubMed ID: 10402157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of SR 141716A after acute or chronic cannabinoid administration in dogs.
    Lichtman AH; Wiley JL; LaVecchia KL; Neviaser ST; Arthur DB; Wilson DM; Martin BR
    Eur J Pharmacol; 1998 Sep; 357(2-3):139-48. PubMed ID: 9797029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A synthetic cannabinoid, CP55940, inhibits lipopolysaccharide-induced cytokine mRNA expression in a cannabinoid receptor-independent mechanism in rat cerebellar granule cells.
    Chiba T; Ueno S; Obara Y; Nakahata N
    J Pharm Pharmacol; 2011 May; 63(5):636-47. PubMed ID: 21492165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.